Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 7

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 7
---
 strategy and to align with upcoming mandatory ESG disclosure requirements. More details regarding our double materiality process and the subsequent outcomes will be reported in future ESG disclosures.​​
8 | 2025 Proxy Statement

| ​ | ​             |
| ​ | PROXY SUMMARY |

Below are select 2024 ESG highlights:

| ​ |

| ​                                                                                                                                                                             |   |                                                                                                                                                                            |   |                                                                                                                                                 |
| ✓Decreased our Scope 1 and 2 emissions by more than 26% compared to our 2021 baseline, and ahead of schedule to meet our 42% Scope 1 and 2 emissions reduction target by 2030 
 ✓Increased our active sourcing of renewable electricity by 55% compared to our 2021 baseline, more than halfway to our 2030 target of 100%                                    
 ✓Exceeded our target to reduce absolute hazardous and non-hazardous waste generated by 20% by 2025 compared to our 2015 baseline                                              
 ✓Certified seven of our manufacturing sites as Zero Waste to Landfill facilities as of 2024                                                                                   | ​ | ✓$10.8 billion in adjusted research & development investment in 20241                                                                                                      
 ✓Over 235,000 U.S. patients provided medicine at no cost through our patient assistance program in 2024                                                                    
 ✓9 product or indication approvals in 2024                                                                                                                                 
 ✓Over 13,000 AbbVie employees in nearly 60 countries and territories donated more than 47,000 volunteer hours during AbbVie’s annual Week of Possibilities volunteer event | ​ | ✓Appointed Robert Michael as AbbVie’s CEO in July 2024, succeeding Richard Gonzalez who assumed the position of Executive Chairman of the Board 
 ✓Added three new board directors in the past two years                                                                                          
 ✓99% of employees completed AbbVie’s annual training on our Code of Business Conduct and conflicts of interest training2                        
 ✓Launched our new sustainable supply chain survey to over 100 critical suppliers, attaining a 91% response rate                                 |

1Adjusted research and development investment is a non-GAAP measure, which is reconciled in Appendix B. 2Employees who did not complete these trainings include, but are not limited to, those who are on leave of absence, retired or otherwise left the company prior to completion date.

2025 Proxy Statement |9

| ​             | ​ |
| PROXY SUMMARY | ​ |

| ​External Recognition as a Leading Company |

Our work hasn’t gone unnoticed